Clinical Trial Update: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Niraparib to placebo in HER2-negative breast cancer with BRCA mutation or triple-negative disease, with results reporting efficacy and s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Niraparib (Niraparib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Breast | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-07-16